Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lamelleye is a topical ophthalmic product developed for the treatment of moderate to severe dry eye disease (DED). It utilizes Lamellasome technology, which mimics the actions of serous lamellar bodies—structures that regulate interfaces between tissues and external environments. The formulation contains multilamellar lipid vesicles designed to restore and stabilize the tear film, providing unique lubricating and muco-restorative properties. This biophysical mechanism aims to address underlying causes of dry eye by improving mucosal surface hydration and reducing tear evaporation. Lamelleye received CE Mark clearance in the European Union in 2015, supporting its commercialization as a medical device for DED[6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lamelleye.